Conversation with The Cancer Letter

Roy Jensen describes KU’s 18-year path to Comprehensive designation

Some things are known to grow well in Kansas. Some things aren’t. Over the past 18 years, Roy Jensen has been told time and again that it made no sense to even try to grow an NCI-designated Comprehensive Cancer Center in Kansas. Yet, he did the only thing he could. Persist. Stubbornly. The University of... […]

July 08, 2022

Vol.48 No.27

By Paul Goldberg

Conversation with The Cancer Letter Free

Ohio State’s Alice Mims: Six-week abortion ban places oncologists in jeopardy

As conservative legislatures take the cue from the Supreme Court’s overturn of Roe v. Wade by enacting abortion restrictions, oncologists in many states are scrambling to figure out how to best care for their pregnant patients, said Alice Mims, a hematologist-oncologist at the Ohio State University Comprehensive Cancer Center – James.

July 08, 2022

Vol.48 No.27

By Alice Tracey

Conversation with The Cancer Letter Free

Harvard Law’s I. Glenn Cohen: To provide good care, doctors will run afoul of criminal law in some states as Roe v. Wade ends

Now that the constitutional right to abortion has been eliminated, U.S. healthcare providers have to choose one of three options: give up abortion services, relocate, or wrangle with enforcement and unfriendly state legislatures.

July 01, 2022

Vol.48 No.26

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Julie Bauman: Washington, DC, needs one more NCI-designated cancer center—and it matters that a woman runs it

As she was interviewing for the director’s job at the George Washington Cancer Center, Julie E. Bauman was asked what her biggest fear would be.

June 17, 2022

Vol.48 No.24

By Paul Goldberg

Conversation with The Cancer Letter

ATOM Coalition sees patent sharing as key to overcoming scarcity of cancer drugs in LLMICs

Cancer organizations and pharmaceutical companies have formed a coalition that seeks to develop licensing agreements to improve access to essential cancer drugs in low- and lower-middle income countries (LLMICs).

June 03, 2022

Vol.48 No.22

By Alice Tracey

Cancer History Project Conversation with The Cancer Letter Free

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

When Judy Orem learned of her chronic myeloid leukemia diagnosis in 1995, she chose interferon over a treatment that seemed more risky—a bone marrow transplant.

June 03, 2022

Vol.48 No.22

By Deborah Doroshow and Alexandria Carolan

Conversation with The Cancer Letter

Jon Chernoff pledges to revive his institution’s “Fox Chaseness” after years of setbacks

Fox Chase Cancer Center used to be a place where Nobel laureates toiled. Now, people who love the place—and in oncology, many people do—are hoping that Jonathan Chernoff, Fox Chase’s new director, will restore vitality to the venerable Philadelphia-based cancer center.

May 20, 2022

Vol.48 No.20

By Paul Goldberg

Conversation with The Cancer Letter

FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done

FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.

May 06, 2022

Vol.48 No.18

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Romania’s Csaba Dégi: We need to be proactive about psychosocial support, because Ukrainians are suffering

Ukrainian refugees and displaced persons with cancer are fighting a double war for survival—which is why aid networks and providers must prioritize psychosocial oncology, said Csaba Dégi, executive secretary of the International Psycho-Oncology Society.

April 22, 2022

Vol.48 No.16

By Matthew Bin Han Ong

Conversation with The Cancer Letter

At ODAC without sponsors, FDA highlights safety signals in PI3K inhibitor trials

Why is the April 21 ODAC different from all the other ODACs? At all other ODACs, a commercial sponsor gets to make a case. On April 21, only FDA’s voice will be heard.

April 15, 2022

Vol.48 No.15

By Paul Goldberg

Conversation with The Cancer Letter

Roy Jensen describes KU’s 18-year path to Comprehensive designation

Ohio State’s Alice Mims: Six-week abortion ban places oncologists in jeopardy

Harvard Law’s I. Glenn Cohen: To provide good care, doctors will run afoul of criminal law in some states as Roe v. Wade ends

Julie Bauman: Washington, DC, needs one more NCI-designated cancer center—and it matters that a woman runs it

ATOM Coalition sees patent sharing as key to overcoming scarcity of cancer drugs in LLMICs

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

Jon Chernoff pledges to revive his institution’s “Fox Chaseness” after years of setbacks

FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done

Romania’s Csaba Dégi: We need to be proactive about psychosocial support, because Ukrainians are suffering

At ODAC without sponsors, FDA highlights safety signals in PI3K inhibitor trials

Renew today!

Subscriber content

Never miss an issue!

Login